多动症儿童和青少年基于症状、功能损害及生活质量的临床试验结果之间的相关性
Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD.
作者信息
Coghill David R, Joseph Alain, Sikirica Vanja, Kosinski Mark, Bliss Caleb, Huss Michael
机构信息
1 University of Melbourne, Victoria, Australia.
2 University of Dundee, UK.
出版信息
J Atten Disord. 2017 Aug 24;23(13):1578-1591. doi: 10.1177/1087054717723984. Print 2019 Nov 1.
OBJECTIVE
To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD.
METHOD
Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference).
RESULTS
Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance ( r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort ( r ≈ .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score ( r ≈ .5).
CHIP-CE: PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score ( r ≈ .6).
CONCLUSION
The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.
目的
评估多动症儿童和青少年中，与治疗相关的多动症症状测量指标、功能损害及健康相关生活质量变化之间的关系。
方法
对一项右苯丙胺（渗透释放型哌甲酯对照）随机、安慰剂和活性对照试验以及一项缓释胍法辛（托莫西汀对照）试验中，从基线到终点的结果变化进行事后计算Pearson相关系数。
结果
多动症评定量表第四版（ADHD-RS-IV）总分的变化一般与儿童健康与疾病概况-儿童版：家长报告表（CHIP-CE:PRF）成就与风险规避变化中度相关（r≈0.4），但与恢复力、满意度和舒适度变化弱相关（r≈0.2）；与韦斯功能损害评定量表-家长版（WFIRS-P）总分中度相关（r≈0.5）。
CHIP-CE:PRF成就与风险规避与WFIRS-P总分中度至高度相关（r≈0.6）。
结论
ADHD-RS-IV、CHIP-CE:PRF和WFIRS-P反映了多动症个体治疗反应中不同但相互关联的方面。
Zotero 插件